These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15255171)

  • 1. Graft purging in autologous bone marrow transplantation: a promise not quite fulfilled.
    Alvarnas JC; Forman SJ
    Oncology (Williston Park); 2004 Jun; 18(7):867-76; discussion 876-8, 881, 884. PubMed ID: 15255171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ex vivo purging with CliniMACS CD34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma.
    Yahng SA; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Min WS; Park CW; Kim Y; Cho SG
    Br J Haematol; 2014 Feb; 164(4):555-64. PubMed ID: 24266323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone marrow transplantation for leukemia.
    Stuart RK
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo purging and relapse prevention following ASCT.
    Gisselbrecht C
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S5-9. PubMed ID: 11840154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future paradigm for autologous bone marrow transplantation: tumor purging and ex vivo production of normal stem and progenitor cells.
    Rummel SA; Van Zant G
    J Hematother; 1994; 3(3):213-8. PubMed ID: 7827869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry.
    Williams CD; Goldstone AH; Pearce RM; Philip T; Hartmann O; Colombat P; Santini G; Foulard L; Gorin NC
    J Clin Oncol; 1996 Sep; 14(9):2454-64. PubMed ID: 8823323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations.
    Negrin RS; Pesando J
    J Clin Oncol; 1994 May; 12(5):1021-7. PubMed ID: 8164025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
    Gribben JG; Freedman AS; Neuberg D; Roy DC; Blake KW; Woo SD; Grossbard ML; Rabinowe SN; Coral F; Freeman GJ
    N Engl J Med; 1991 Nov; 325(22):1525-33. PubMed ID: 1944436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of amifostine in bone marrow purging.
    Cagnoni PJ; Jones RB; Bearman SI; Ross M; Hami L; Franklin WA; Capizzi R; Schein PS; Shpall EJ
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):44-8. PubMed ID: 8783666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo expansion of normal progenitor cells from acute myeloid leukemia cell-contaminated CD34+ peripheral blood progenitor cells after mafosfamide purging.
    Stilz R; Grünebach F; Bader P; Vogel W; Kanz L; Brugger W; Scheding S
    J Hematother Stem Cell Res; 2001 Dec; 10(6):777-85. PubMed ID: 11798504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma.
    Berinstein NL; Buckstein R; Imrie K; Spaner D; Mangel J; Tompkins K; Pennell N; Reis M; Pavlin P; Lima A; Couvadia A; Robinson J; Richardson P
    Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S14-7. PubMed ID: 11840156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
    Bierman PJ; Sweetenham JW; Loberiza FR; Taghipour G; Lazarus HM; Rizzo JD; Schmitz N; van Besien K; Vose JM; Horowitz M; Goldstone A;
    J Clin Oncol; 2003 Oct; 21(20):3744-53. PubMed ID: 12963703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of CD34 selection and complement-mediated immunopurging (anti-CD15 monoclonal antibody) eliminates tumor cells while sparing normal progenitor cells.
    Nimgaonkar M; Kemp A; Lancia J; Ball ED
    J Hematother; 1996 Feb; 5(1):39-48. PubMed ID: 8646480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation.
    LaCasse EC; Bray MR; Patterson B; Lim WM; Perampalam S; Radvanyi LG; Keating A; Stewart AK; Buckstein R; Sandhu JS; Miller N; Banerjee D; Singh D; Belch AR; Pilarski LM; Gariépy J
    Blood; 1999 Oct; 94(8):2901-10. PubMed ID: 10515895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
    Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
    Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
    Schriber JR; Negrin RS; Chao NJ; Long GD; Horning SJ; Blume KG
    Leukemia; 1993 Oct; 7(10):1491-5. PubMed ID: 7692189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.